In recent years, sodium–glucose cotransporter 2 (SGLT2) inhibitors have been found to increase the risk of DKA, most often when used in type 1 diabetes but also in type 2 diabetes [2]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.